Theralink® Acquires Two New Milestone Patents Relating to Methods for Treating Breast Cancer

Predictive Biomarker Patents may improve Outcomes for Breast Cancer Patients Patent Portfolio increases to Nine GOLDEN, Colo., July 25, 2022 /PRNewswire/ — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel…

Click here to view original post